Cargando…

Secondary Progressive Multiple Sclerosis: New Insights

In most cases, multiple sclerosis (MS) begins with a relapsing-remitting course followed by insidious disability worsening that is independent from clinically apparent relapses and is termed secondary progressive MS (SMPS). Major differences exist between relapsing-remitting MS (RRMS) and SPMS, espe...

Descripción completa

Detalles Bibliográficos
Autores principales: Cree, Bruce A.C., Arnold, Douglas L., Chataway, Jeremy, Chitnis, Tanuja, Fox, Robert J., Pozo Ramajo, Angela, Murphy, Niamh, Lassmann, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397587/
https://www.ncbi.nlm.nih.gov/pubmed/34088878
http://dx.doi.org/10.1212/WNL.0000000000012323
_version_ 1783744649455730688
author Cree, Bruce A.C.
Arnold, Douglas L.
Chataway, Jeremy
Chitnis, Tanuja
Fox, Robert J.
Pozo Ramajo, Angela
Murphy, Niamh
Lassmann, Hans
author_facet Cree, Bruce A.C.
Arnold, Douglas L.
Chataway, Jeremy
Chitnis, Tanuja
Fox, Robert J.
Pozo Ramajo, Angela
Murphy, Niamh
Lassmann, Hans
author_sort Cree, Bruce A.C.
collection PubMed
description In most cases, multiple sclerosis (MS) begins with a relapsing-remitting course followed by insidious disability worsening that is independent from clinically apparent relapses and is termed secondary progressive MS (SMPS). Major differences exist between relapsing-remitting MS (RRMS) and SPMS, especially regarding therapeutic response to treatment. This review provides an overview of the pathology, differentiation, and challenges in the diagnosis and treatment of SPMS. We emphasize the criticality of conversion from a relapsing-remitting to a secondary progressive disease course not only because such conversion is evidence of disability progression, but also because, until recently, treatments that effectively reduced disability progression in relapsing MS were not proven to be effective in SPMS. Clear clinical, imaging, immunologic, or pathologic criteria marking the transition from RRMS to SPMS have not yet been established. Early identification of SPMS will require tools that, together with the use of appropriate treatments, may result in better long-term outcomes for the population of patients with SPMS.
format Online
Article
Text
id pubmed-8397587
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-83975872021-08-31 Secondary Progressive Multiple Sclerosis: New Insights Cree, Bruce A.C. Arnold, Douglas L. Chataway, Jeremy Chitnis, Tanuja Fox, Robert J. Pozo Ramajo, Angela Murphy, Niamh Lassmann, Hans Neurology Review In most cases, multiple sclerosis (MS) begins with a relapsing-remitting course followed by insidious disability worsening that is independent from clinically apparent relapses and is termed secondary progressive MS (SMPS). Major differences exist between relapsing-remitting MS (RRMS) and SPMS, especially regarding therapeutic response to treatment. This review provides an overview of the pathology, differentiation, and challenges in the diagnosis and treatment of SPMS. We emphasize the criticality of conversion from a relapsing-remitting to a secondary progressive disease course not only because such conversion is evidence of disability progression, but also because, until recently, treatments that effectively reduced disability progression in relapsing MS were not proven to be effective in SPMS. Clear clinical, imaging, immunologic, or pathologic criteria marking the transition from RRMS to SPMS have not yet been established. Early identification of SPMS will require tools that, together with the use of appropriate treatments, may result in better long-term outcomes for the population of patients with SPMS. Lippincott Williams & Wilkins 2021-08-24 /pmc/articles/PMC8397587/ /pubmed/34088878 http://dx.doi.org/10.1212/WNL.0000000000012323 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Review
Cree, Bruce A.C.
Arnold, Douglas L.
Chataway, Jeremy
Chitnis, Tanuja
Fox, Robert J.
Pozo Ramajo, Angela
Murphy, Niamh
Lassmann, Hans
Secondary Progressive Multiple Sclerosis: New Insights
title Secondary Progressive Multiple Sclerosis: New Insights
title_full Secondary Progressive Multiple Sclerosis: New Insights
title_fullStr Secondary Progressive Multiple Sclerosis: New Insights
title_full_unstemmed Secondary Progressive Multiple Sclerosis: New Insights
title_short Secondary Progressive Multiple Sclerosis: New Insights
title_sort secondary progressive multiple sclerosis: new insights
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397587/
https://www.ncbi.nlm.nih.gov/pubmed/34088878
http://dx.doi.org/10.1212/WNL.0000000000012323
work_keys_str_mv AT creebruceac secondaryprogressivemultiplesclerosisnewinsights
AT arnolddouglasl secondaryprogressivemultiplesclerosisnewinsights
AT chatawayjeremy secondaryprogressivemultiplesclerosisnewinsights
AT chitnistanuja secondaryprogressivemultiplesclerosisnewinsights
AT foxrobertj secondaryprogressivemultiplesclerosisnewinsights
AT pozoramajoangela secondaryprogressivemultiplesclerosisnewinsights
AT murphyniamh secondaryprogressivemultiplesclerosisnewinsights
AT lassmannhans secondaryprogressivemultiplesclerosisnewinsights